Certified by Founder Lodge
Ascenta Capital
United States - ND
INVESTOR
1 Disclosed Funding Rounds $200,000,000
7 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Ascenta Capital invests in biotechs.
| Company | Date | Round | Raised |
|---|---|---|---|
 Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
 ADARx Pharmaceuticals Inc. |
August, 10 ,2023 | Series C | $200,000,000 |
 Tubulis GmbH |
October, 16 ,2025 | Series C | $359,197,300 |
 Iambic Therapeutics |
October, 06 ,2023 | Series B | $100,000,000 |
 Odyssey Therapeutics |
December, 06 ,2023 | Series C | $101,000,000 |
| Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
| Tubulis GmbH |
October, 16 ,2025 | Series C | $359,197,300 |
Cherry Ventures
Blue Bear Capital
Slow Ventures
Climate Capital
Eniac Ventures
Sizable Energy | $8,000,000 | (Oct 24, 2025)
Sumble | $38,500,000 | (Oct 24, 2025)
Syntracts | $5,300,000 | (Oct 24, 2025)
Cybrid | $10,000,000 | (Oct 24, 2025)
Elevara Medicines | $70,000,000 | (Oct 24, 2025)
